Emergent BioSolutions (EBS) announced that it has partnered with the B.C. Provincial Health Services Authority to supply Narcan Nasal Spray for the province’s Take-Home Naloxone Program. This order follows an additional investment of C$18M by the B.C. government to expand the BC THN Program to include nasal naloxone. This is an expansion of B.C.’s nasal naloxone pilot program, which launched in 2024, and provided 60,000 nasal naloxone kits to community sites, pharmacies, post-secondary institutions, First-Nations-mandated institutions, fire departments, municipalities and libraries.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Trump Trade: Zuckerberg, Ellison, Huang named to Trump’s tech panel
- Contract Momentum and Biodefense Tailwinds Underpin Buy Rating on Emergent BioSolutions
- Emergent BioSolutions announces over $60M in government contract awards
- Emergent BioSolutions price target lowered to $12 from $15 at H.C. Wainwright
- Emergent BioSolutions Adds Independent Director Amid Turnaround Efforts